Study Reveals New Target for Treating C. difficile Infection

A new study paves the way for the development of next-generation therapeutics for the prevention and treatment of Clostridioides difficile infection (CDI), the most frequent cause of healthcare-acquired gastrointestinal infections and death in developed countries. Published online on June 18, 2021 in Nature Communications, the study reveals the first 3D structure of the Clostridioides difficile toxin B (TcdB) in complex with chondroitin sulfate proteoglycan 4 (CSPG4), a human receptor. The open-access article is titled “Structural Basis for CSPG4 As a Receptor for TcdB and a Therapeutic Target in Clostridioides difficile Infection.” The study was co-led by senior author Rongsheng Jin, PhD, a Professor in the Department of Physiology & Biophysics at the University of California, Irvine, School of Medicine, and Min Dong, PhD, an Associate Professor at Harvard Medical School.
Login Or Register To Read Full Story